How Bayer's Engineered Antibodies Help Blood Clotting
This patent describes specific engineered antibodies designed to block a protein that prevents blood clotting, potentially helping people with bleeding disorders.
Original patent title: “USRE47150E1 - Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)”
This patent describes specific engineered antibodies designed to block a protein that prevents blood clotting, potentially helping people with bleeding disorders. Granted to Bayer Healthcare LLC in 2018 with 28 claims.
Key facts
Coverage
What does this patent actually cover?
The patent covers a specific type of human monoclonal IgG antibody that binds to a protein called Tissue Factor Pathway Inhibitor (TFPI). TFPI normally acts as a brake on the body's blood-clotting process. By binding to and inhibiting TFPI, these engineered antibodies effectively remove that brake, which can help promote clotting in patients who have deficiencies in their blood coagulation system. The claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → specify exact amino acid sequences and precise substitutions (like K55Y or D62R) within the antibody's binding regions (CDRs) to ensure the antibody attaches to TFPI with high specificity.
The gap
What does this patent NOT cover?
- Does not cover naturally occurring antibodies found in the human body.
- Does not cover antibodies that bind to proteins other than TFPI.
- Does not cover therapeutic methods that use small-molecule drugs instead of monoclonal antibodies.
- Does not cover antibodies lacking the specific amino acid substitutions defined in the claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
What made this novel
The innovation lies in the specific amino acid 'tuning' of the antibody's binding loops (CDRs). By making precise substitutions at key positions, the inventors increased the antibody's affinity for TFPI, making the treatment more potent and effective at lower doses.
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Experimental hemophilia therapies
Targeted monoclonal antibody drug candidates for coagulation disorders
Why it matters
The bigger picture
This technology is significant for treating hemophilia and other bleeding disorders where the body struggles to form stable clots. By targeting TFPI, these antibodies offer an alternative approach to traditional factor replacement therapies, which require frequent injections. This patent represents a core intellectual property asset for Bayer in the development of potential hemophilia treatments.
Filed
March 1, 2011
Granted
December 4, 2018
Market context
Who's building on this
Companies in this space
Bayer Healthcare remains the primary entity associated with this patent. The broader field of anti-TFPI therapy is also explored by other large pharmaceutical companies and biotech firms focused on hematology and coagulation research.
Market impact
This patent secures a specific molecular approach to managing blood clotting, providing Bayer with a competitive position in the development of non-factor replacement therapies. It contributes to the broader industry shift toward using engineered monoclonal antibodies to treat chronic bleeding disorders.
Claim 1 — Plain English
What this patent covers
The patent covers a specific type of human monoclonal IgG antibody that binds to a protein called Tissue Factor Pathway Inhibitor (TFPI). TFPI normally acts as a brake on the body's blood-clotting process. By binding to and inhibiting TFPI, these engineered antibodies effectively remove that brake, which can help promote clotting in patients who have deficiencies in their blood coagulation system. The claims specify exact amino acid sequences and precise substitutions (like K55Y or D62R) within the antibody's binding regions (CDRs) to ensure the antibody attaches to TFPI with high specificity.
The clever bit
The innovation lies in the specific amino acid 'tuning' of the antibody's binding loops (CDRs). By making precise substitutions at key positions, the inventors increased the antibody's affinity for TFPI, making the treatment more potent and effective at lower doses.
What it does not cover
- Does not cover naturally occurring antibodies found in the human body.
- Does not cover antibodies that bind to proteins other than TFPI.
- Does not cover therapeutic methods that use small-molecule drugs instead of monoclonal antibodies.
- Does not cover antibodies lacking the specific amino acid substitutions defined in the claims.
Patent timeline
Application submitted to the patent office
Application published, typically 18 months after filing
Patent officially issued
PatentBrief Score
Impact Score
Early stage
Citation count
0/40
No citations yet
Claim breadth
19/20
Very broad protection
Recency
10/20
Granted 5–10 years ago
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$51K – $164K
Midpoint $102K · 4.7 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
The original legal language
Original claims
28 claims as filed with the patent office.
Concepts involved
Citations
Patent lineage
Cite this patent
Brückner, S., Grudzinska-Goebel, J., Wobst, N., Tebbe, J., Pan, J., Birkenfeld, J., Scholz, P., Votsmeier, C., Wang, Z., & Steinig, S. (2018). How Bayer's Engineered Antibodies Help Blood Clotting (U.S. Patent No. RE47,150). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/RE47150/cosentyx-secukinumab
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="USRE47150"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does How Bayer's Engineered Antibodies Help Blood Clotting cover?
This patent describes specific engineered antibodies designed to block a protein that prevents blood clotting, potentially helping people with bleeding disorders.
Who owns patent US RE47150?
Bayer Healthcare LLC owns this patent, granted in 2018.
When does this patent expire?
This patent is expected to expire on December 4, 2038, when the invention enters the public domain.
What problem does this patent solve?
This technology is significant for treating hemophilia and other bleeding disorders where the body struggles to form stable clots. By targeting TFPI, these antibodies offer an alternative approach to traditional factor replacement therapies, which require frequent injections. This patent represents a core intellectual property asset for Bayer in the development of potential hemophilia treatments.
What does this patent NOT cover?
Does not cover naturally occurring antibodies found in the human body.
Patent monitoring